logo
logo

Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology

Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology

01/19/21, 4:14 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgwashington
Money raised
$1 million
Industry
health care
Round Type
seed
 Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), today announced a $1 million programmatic investment in Satellos Bioscience Inc. (Satellos) to support the development of a new regenerative medicine for the therapeutic treatment of Duchenne.

Company Info

Company
Parent Project Muscular Dystrophy:
Location
washington, united states
Additional Info
Duchenne is a genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) fights every single battle necessary to end Duchenne. We demand optimal care standards and ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won seven FDA approvals. Everything we do—and everything we have done since our founding in 1994—helps those with Duchenne live longer, stronger lives. We will not rest until we end Duchenne for every single person affected by the disease. To learn more about PPMD's robust Research Strategy, click here. Join our fight against Duchenne at EndDuchenne.org. Follow PPMD on Facebook, Twitter, Instagram, and YouTube.

Related People